MedTrace Logo

Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients

NCT03470961 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-03-20

No results posted yet for this study

Summary

A single-centre, prospective, observational study to evaluate the safety and efficacy of Polyclonal Antibodies in simultaneous Pancreas Kidney Transplant recipients.

Conditions

  • CKD (Chronic Kidney Disease) Stage 5T
  • Diabetes Mellitus
  • Simultaneous Pancreas Kidney Transplantation

Interventions

DRUG

Anti-Tlymphocyte Globulins

Induction therapy regimen in simultaneous pancreas kidney transplantation

DRUG

Anti-Thymocyte Globulins

Induction therapy regimen in simultaneous pancreas kidney transplantation

Sponsors & Collaborators

  • Tianjin First Central Hospital

    lead OTHER

Principal Investigators

  • Yingxin FU, M.D · Tianjin First Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2021-03-01
Completion
2021-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03470961 on ClinicalTrials.gov